Bartlett & Co Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Bartlett & Co Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.77K	Hold	200	–	–	﹤0.01%	1088
2025 Q4	$1.8K	Hold	200	–	–	﹤0.01%	1126
2025 Q3	$3.45K	Hold	200	–	–	﹤0.01%	1045
2025 Q2	$1.88K	Hold	200	–	–	﹤0.01%	1101
2025 Q1	$1.42K	Hold	200	–	–	﹤0.01%	1089
2024 Q4	$2.33K	Hold	200	–	–	﹤0.01%	1030
2024 Q3	$4.11K	Hold	200	–	–	﹤0.01%	992
2024 Q2	$4.48K	Hold	200	–	–	﹤0.01%	994
2024 Q1	$5.5K	Hold	200	–	–	﹤0.01%	965
2023 Q4	$6.35K	Hold	200	–	–	﹤0.01%	1053
2023 Q3	$6.32K	Hold	200	–	–	﹤0.01%	972
2023 Q2	$8.16K	Hold	200	–	–	﹤0.01%	943
2023 Q1	$7.45K	Hold	200	–	–	﹤0.01%	848
2022 Q4	$6.98K	Hold	200	–	–	﹤0.01%	871
2022 Q3	$11.2K	Hold	200	–	–	﹤0.01%	806
2022 Q2	$10.4K	Hold	200	–	–	﹤0.01%	860
2022 Q1	$14.5K	Buy	+200	New	+$16.9K	﹤0.01%	776

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bartlett & Co Wealth Management's NTLA Position: Q1 2026 in Review

Bartlett & Co Wealth Management held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 200 shares worth $2.77K. The position accounts for ﹤0.01% of the portfolio, ranked #1088.

Bartlett & Co Wealth Management first reported a position in NTLA in Q1 2022 and has held it in 17 quarters since. The position peaked at $14.5K in Q1 2022. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Bartlett & Co Wealth Management held 200 shares of Intellia Therapeutics worth $2.77K as of Q1 2026.
Bartlett & Co Wealth Management left its Intellia Therapeutics share count unchanged in Q1 2026.
Intellia Therapeutics made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q1 2026, its #1088 holding.
Bartlett & Co Wealth Management first reported a position in Intellia Therapeutics in Q1 2022 and has held it in 17 quarters since.
Bartlett & Co Wealth Management's Intellia Therapeutics position peaked at $14.5K in Q1 2022.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.